FRI469 Natural History Of de Quervain’s Thyroiditis In The Era Of COVID -19: The Greek Experience Of 226 Cases

Disclosure: N. Angelopoulos: None. D.P. Askitis: None. I. Androulakis: None. N. Valvis: None. R. Paparodis: None. V. Petkova: None. A. Boniakos: None. D. Zianni: None. I. Perogamvros: None. K.A. Toulis: None. S. Livadas: None. Background: Subacute thyroiditis (SAT) is a usually self-limiting disease however,patients with pronounced tenderness normally receive nonsteroidal anti-inflammatorydrugs (NSAIDs) or systemic steroids. Disease recurrence is unfortunately common, while approximately 0.5-15% of patients require permanent thyroxine substitution. Among the thyroid SARS-CoV-2 complications, SAT was reported early and the question whether SAT might be underestimated was raised. Aims and Scope: The aims of this retrospective study were: (1) to determine predictive factors for SAT recurrence and the development of hypothyroidism and (2) to identify potential clinical and laboratory characteristics in patients with SAT due to SARS-CoV-2 infection. Methods: We retrospectively reviewed the records of 226 patients with confirmed subacute thyroiditis between January 2020 and November 2022 in eleven outpatient endocrine clinics with geographical representativeness of Greek territory. Results: Mean age was 48.01 years and F/M 158/68. Baseline hypothyroidism was present in 11 patients (4.86%), 36 had Hashimoto, 30 had nodular disease, 4 had both Hashimoto and nodules, 1 was hyperthyroid and the remaining 144 patients had no thyroid disease. At the end of follow up (16.77±0.8 months) 68 patients (34.5%) had hypothyroidism (P